solo para uso en investigación
Cat. No.S7680
| Dianas relacionadas | HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK |
|---|---|
| Otros Histone Demethylase Inhibidores | GSK-J4 Hydrochloride GSK-LSD1 2HCl Ladademstat (ORY-1001) Dihydrochloride JIB-04 CPI-455 HCl OG-L002 IOX1 GSK J1 ML324 CPI-455 |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| U87 | Growth inhibition assay | 96 h | Growth inhibition of human U87 cells after 96 hrs by ATPlite luminescence assay IC50=1.16 μM | 24237195 | ||
| SK-N-MC | Growth inhibition assay | 96 h | Growth inhibition of human SK-N-MC cells after 96 hrs by ATPlite luminescence assay IC50=0.329 μM | 24237195 | ||
| T47D | Growth inhibition assay | 96 h | Growth inhibition of human T47D cells after 96 hrs by ATPlite luminescence assay IC50=0.649 μM | 24237195 | ||
| PC3 | Growth inhibition assay | 96 h | Growth inhibition of human PC3 cells after 96 hrs by ATPlite luminescence assay IC50=2.16 μM | 24237195 | ||
| PANC1 | Growth inhibition assay | 96 h | Growth inhibition of human PANC1 cells after 96 hrs by ATPlite luminescence assay IC50=1.104 μM | 24237195 | ||
| MIAPaCa2 | Growth inhibition assay | 96 h | Growth inhibition of human MIAPaCa2 cells after 96 hrs by ATPlite luminescence assay IC50=0.468 μM | 24237195 | ||
| MDA-MB-468 | Growth inhibition assay | 96 h | Growth inhibition of human MDA-MB-468 cells after 96 hrs by ATPlite luminescence assay IC50=2.73 μM | 24237195 | ||
| MDA-MB-435 | Growth inhibition assay | 96 h | Growth inhibition of human MDA-MB-435 cells after 96 hrs by ATPlite luminescence assay IC50=1.44 μM | 24237195 | ||
| MDA-MB-231 | Growth inhibition assay | 96 h | Growth inhibition of human MDA-MB-231 cells after 96 hrs by ATPlite luminescence assay IC50=1.04 μM | 24237195 | ||
| MCF7 | Growth inhibition assay | 96 h | Growth inhibition of human MCF7 cells after 96 hrs by ATPlite luminescence assay IC50=0.637 μM | 24237195 | ||
| HT-29 | Growth inhibition assay | 96 h | Growth inhibition of human HT-29 cells after 96 hrs by ATPlite luminescence assay IC50=0.429 μM | 24237195 | ||
| Hs | Growth inhibition assay | 96 h | Growth inhibition of human Hs 578T cells after 96 hrs by ATPlite luminescence assay IC50=1.7 μM | 24237195 | ||
| HER218 | Growth inhibition assay | 96 h | Growth inhibition of human HER218 cells after 96 hrs by ATPlite luminescence assay IC50=0.612 μM | 24237195 | ||
| HCT116 | Growth inhibition assay | 96 h | Growth inhibition of human HCT116 cells after 96 hrs by ATPlite luminescence assay IC50=0.614 μM | 24237195 | ||
| BT20 | Growth inhibition assay | 96 h | Growth inhibition of human BT20 cells after 96 hrs by ATPlite luminescence assay IC50=0.489 μM | 24237195 | ||
| BT549 | Growth inhibition assay | 96 h | Growth inhibition of human BT549 cells after 96 hrs by ATPlite luminescence assay IC50=1.01 μM | 24237195 | ||
| AN3CA | Growth inhibition assay | 96 h | Growth inhibition of human AN3CA cells after 96 hrs by ATPlite luminescence assay IC50=0.356 μM | 24237195 | ||
| HCT116 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human HCT116 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 0.33 μM. | 27524309 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 0.44 μM. | 27524309 | ||
| DU145 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human DU145 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 0.62 μM. | 27524309 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 0.65 μM. | 27524309 | ||
| MDA-MB-231 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human MDA-MB-231 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 0.75 μM. | 27524309 | ||
| A2780 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human A2780 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 0.77 μM. | 27524309 | ||
| A549 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human A549 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 0.83 μM. | 27524309 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-231 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 1.4 μM. | 27524309 | ||
| NCI-H1299 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human NCI-H1299 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 1.73 μM. | 27524309 | ||
| A2780 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A2780 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 2.14 μM. | 27524309 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 2.69 μM. | 27524309 | ||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H1299 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 3.01 μM. | 27524309 | ||
| PC3 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human PC3 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 4.45 μM. | 27524309 | ||
| SMMC7721 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human SMMC7721 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay, IC50 = 5.36 μM. | 27524309 | ||
| DU145 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human DU145 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 13.08 μM. | 27524309 | ||
| LSD1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SMMC7721 over-expressing LSD1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 15.75 μM. | 27524309 | ||
| PC3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human PC3 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay, IC50 = 19.72 μM. | 27524309 | ||
| H460 | Antiproliferative assay | 48 to 72 hrs | Antiproliferative activity against human H460 cells after 48 to 72 hrs by MTT assay, IC50 = 0.47 μM. | 29754076 | ||
| MCF7 | Antiproliferative assay | 48 to 72 hrs | Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay, IC50 = 0.62 μM. | 29754076 | ||
| Raji | Antiproliferative assay | 48 to 72 hrs | Antiproliferative activity against human Raji cells after 48 to 72 hrs by MTT assay, IC50 = 0.98 μM. | 29754076 | ||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 437.90 | Fórmula | C19H20ClN3O5S |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 1423715-09-6 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | HCI-2509 | Smiles | CC(=NNC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCOCC2)C3=C(C=CC(=C3)Cl)O | ||
|
In vitro |
DMSO
: 83 mg/mL
(189.54 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
LSD1
(Cell-free assay) 13 nM
|
|---|---|
| In vitro |
En células AML, SP2509 inhibe la asociación de LSD1 con CoREST, aumenta el H3K4Me3 específico del promotor e induce p53, p21 y C/EBPα. Este compuesto también inhibe significativamente el crecimiento de colonias e induce la apoptosis de OCI-AML3.
|
| Ensayo de quinasa |
Ensayos de actividad de SP2509
|
|
Los compuestos de prueba se diluyen a 20 veces la concentración de prueba deseada en 100% DMSO y se añaden 2,5 μL de la muestra de fármaco diluida a una placa negra de 384 pocillos. El stock de enzima LSD1 se diluye 17 veces con tampón de ensayo y se añaden 40 μL de la enzima LSD1 diluida a los pocillos apropiados. A continuación, se añade a los pocillos el sustrato, que consiste en peroxidasa de rábano, péptido dimetil K4 correspondiente a los primeros 21 aminoácidos de la cola N-terminal de la histona H3, y 10-acetil-3,7-dihidroxifenoxazina. La resorufina se analiza en un lector de placas Envision con una longitud de onda de excitación de 530 nm y una longitud de onda de emisión de 595 nm. La actividad de este compuesto sobre las otras oxidasas se determina utilizando kits disponibles comercialmente. La actividad de la glucosa oxidasa (que también se une no covalentemente al FAD en una conformación elongada) se determina utilizando el kit de glucosa oxidasa. Los ensayos de MAO se realizan utilizando el kit MAO-glo con MAO-A y MAO-B.
|
Referencias |
Tel: +1-832-582-8158 Ext:3
Si tiene alguna otra consulta, por favor deje un mensaje.